Blueshift Asset Management LLC Buys 5,225 Shares of Hims & Hers Health, Inc. $HIMS

Blueshift Asset Management LLC increased its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 15.6% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 38,809 shares of the company’s stock after acquiring an additional 5,225 shares during the quarter. Hims & Hers Health comprises about 0.6% of Blueshift Asset Management LLC’s portfolio, making the stock its 20th largest holding. Blueshift Asset Management LLC’s holdings in Hims & Hers Health were worth $1,935,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Virtus Advisers LLC bought a new position in shares of Hims & Hers Health during the 2nd quarter valued at about $26,000. Quaker Wealth Management LLC purchased a new stake in shares of Hims & Hers Health in the second quarter worth about $29,000. Bessemer Group Inc. boosted its stake in Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after buying an additional 312 shares during the last quarter. Skandinaviska Enskilda Banken AB publ grew its holdings in Hims & Hers Health by 408.2% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 747 shares of the company’s stock valued at $37,000 after buying an additional 600 shares in the last quarter. Finally, Spire Wealth Management bought a new stake in Hims & Hers Health in the 2nd quarter worth approximately $42,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $37.56 on Tuesday. Hims & Hers Health, Inc. has a 12-month low of $23.97 and a 12-month high of $72.98. The company has a current ratio of 1.88, a quick ratio of 1.64 and a debt-to-equity ratio of 1.67. The firm has a 50-day moving average price of $47.15 and a 200-day moving average price of $50.34. The firm has a market capitalization of $8.55 billion, a PE ratio of 69.56, a price-to-earnings-growth ratio of 7.92 and a beta of 2.41.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a return on equity of 24.67% and a net margin of 6.05%.The business had revenue of $598.98 million during the quarter, compared to analysts’ expectations of $578.99 million. During the same quarter in the previous year, the company posted $0.32 earnings per share. The company’s quarterly revenue was up 49.2% compared to the same quarter last year. Hims & Hers Health has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Hims & Hers Health declared that its board has initiated a stock buyback plan on Monday, November 17th that authorizes the company to buyback $250.00 million in outstanding shares. This buyback authorization authorizes the company to reacquire up to 3% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Insiders Place Their Bets

In related news, CFO Oluyemi Okupe sold 23,187 shares of the company’s stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $36.81, for a total value of $853,513.47. Following the completion of the sale, the chief financial officer directly owned 70,232 shares of the company’s stock, valued at $2,585,239.92. This represents a 24.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Michael Chi sold 900 shares of the stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $58.25, for a total transaction of $52,425.00. Following the transaction, the insider owned 291,439 shares in the company, valued at approximately $16,976,321.75. This represents a 0.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 616,431 shares of company stock worth $32,924,482. 17.71% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

HIMS has been the subject of a number of recent research reports. Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Zacks Research cut shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Bank of America boosted their target price on shares of Hims & Hers Health from $28.00 to $32.00 and gave the stock an “underperform” rating in a report on Tuesday, November 4th. BTIG Research reaffirmed a “buy” rating and issued a $85.00 price target on shares of Hims & Hers Health in a report on Tuesday, November 4th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Monday, November 24th. Two equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Hims & Hers Health has an average rating of “Reduce” and an average price target of $45.27.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.